French pharma company, Sanofi aims to strengthen company’s R&D strategy with the acquisition of Nanobodies specialist Ablynx.
Paris/France – Sanofi has entered into a definitive agreement to buy Belgian biotech company Ablynx for approximately 4.8 billion dollars. Ablynx specialises in the discovery and development of Nanobodies. Hence, with this acquisition, Sanofi aims to strength the company’s R&D strategy.
The French company will also acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of 56 dollars in cash. The transaction was unanimously approved by the Boards of Directors of both the organisations.